Characteristics of study patients
| Variable . | Patients with moyamoya (n = 19) . | Patients without moyamoya (n = 25) . | Total study population (N = 44) . |
|---|---|---|---|
| Sex: male/total (% male) | 13/19 (68.4) | 15/25 (60.0)* | 28/44 (63.6) |
| Age, y, as of 7/1/2000, mean ± SD | 17.1 ± 7.0 | 15.5 ± 7.1* | 16.2 ± 7.0 |
| Age, y, at first stroke, mean ± SD | 7.8 ± 4.3 | 7.4 ± 3.9* | 7.6 ± 4.0 |
| Follow-up time, y, after first stroke median (interquartile range) | 8.1 (5.0 to 11.5) | 4.7 (3.6 to 13.4)* | 6.6 (4.2 to 12.5) |
| Recurrent CVE (%) | 11/19 (57.9) | 7/25 (28.0)† (P = .0457) | 18/44 (40.9) |
| Two recurrent CVEs (%) | 8/19 (42.1) | 2/25 (8.0)† (P = .0075) | 10/44 (22.7) |
| Recurrent TIA (%) | 10/19 (52.6) | 6/25 (24.0)* (P = .0505) | 16/44 (36.4) |
| Recurrent stroke (%) | 4/19 (21.1) | 1/25 (4.0)* (P = .0775) | 5/44 (11.4) |
| Median time, y, to subsequent CVE | 3.08 | ‡ | 13.26 |
| Laboratory test values at time of initial stroke | |||
| HbS (%) | 83.0 ± 15.1 | 86.5 ± 7.2* | 84.6 ± 12.2 |
| Fetal hemoglobin (%) | 10.3 ± 6.6 | 10.2 ± 7.6* | 10.3 ± 6.8 |
| White blood cell count (× 109/L) | 17.9 ± 7.7 | 18.1 ± 4.6* | 17.9 ± 6.8 |
| Hemoglobin (g × dL) | 7.6 ± 1.1 | 7.5 ± 1.2* | 7.5 ± 1.1 |
| Reticulocytes (%) | 12.5 ± 4.8 | 10.0 ± 5.0* | 11.6 ± 4.9 |
| Platelets, (× 106/μL) | 403.3 ± 95.3 | 440.1 ± 120.6* | 414.9 ± 102.0 |
| Variable . | Patients with moyamoya (n = 19) . | Patients without moyamoya (n = 25) . | Total study population (N = 44) . |
|---|---|---|---|
| Sex: male/total (% male) | 13/19 (68.4) | 15/25 (60.0)* | 28/44 (63.6) |
| Age, y, as of 7/1/2000, mean ± SD | 17.1 ± 7.0 | 15.5 ± 7.1* | 16.2 ± 7.0 |
| Age, y, at first stroke, mean ± SD | 7.8 ± 4.3 | 7.4 ± 3.9* | 7.6 ± 4.0 |
| Follow-up time, y, after first stroke median (interquartile range) | 8.1 (5.0 to 11.5) | 4.7 (3.6 to 13.4)* | 6.6 (4.2 to 12.5) |
| Recurrent CVE (%) | 11/19 (57.9) | 7/25 (28.0)† (P = .0457) | 18/44 (40.9) |
| Two recurrent CVEs (%) | 8/19 (42.1) | 2/25 (8.0)† (P = .0075) | 10/44 (22.7) |
| Recurrent TIA (%) | 10/19 (52.6) | 6/25 (24.0)* (P = .0505) | 16/44 (36.4) |
| Recurrent stroke (%) | 4/19 (21.1) | 1/25 (4.0)* (P = .0775) | 5/44 (11.4) |
| Median time, y, to subsequent CVE | 3.08 | ‡ | 13.26 |
| Laboratory test values at time of initial stroke | |||
| HbS (%) | 83.0 ± 15.1 | 86.5 ± 7.2* | 84.6 ± 12.2 |
| Fetal hemoglobin (%) | 10.3 ± 6.6 | 10.2 ± 7.6* | 10.3 ± 6.8 |
| White blood cell count (× 109/L) | 17.9 ± 7.7 | 18.1 ± 4.6* | 17.9 ± 6.8 |
| Hemoglobin (g × dL) | 7.6 ± 1.1 | 7.5 ± 1.2* | 7.5 ± 1.1 |
| Reticulocytes (%) | 12.5 ± 4.8 | 10.0 ± 5.0* | 11.6 ± 4.9 |
| Platelets, (× 106/μL) | 403.3 ± 95.3 | 440.1 ± 120.6* | 414.9 ± 102.0 |
Not significantly different from patients with moyamoya (P > .05).
P < .05.
Median time to subsequent CVE after initial stroke is not estimable for patients without moyamoya because most nonmoyamoya patients did not have a subsequent stroke. However, it can be determined that a lower bound for this measure is 5.01 years and that the median time to subsequent CVE after initial stroke is significantly (P = .0429) greater among patients without moyamoya.